PRAX — Praxis Precision Medicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689548 ·
Last close
$305.06
Market Cap
$8.53B
52W High
$392.70
52W Low
$160.11
ADV30
533,081
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -96,904,000 | -83,720,000 | 1,390,102,000 | 474,761,000 | 49,058,000 |
| Mar 2026 | 0 | — | -105,860,000 | -92,561,000 | 1,460,202,000 | 536,333,000 | 50,241,000 |
| Dec 2025 | 0 | — | -97,044,000 | -88,911,000 | 937,907,000 | 357,329,000 | 59,771,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-321,757,000
Investing CF
$-693,785,000
Financing CF
$1,227,450,000
CapEx
$-1,859,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.80
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,410,523,000
Inventory
—
Receivables
—
ST Investments
$383,472,000
EBIT TTM
$-406,722,000
Pretax Income TTM
$-359,426,000
Interest Exp TTM
—
Analysts
20
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -326,198,000 | -303,268,000 | 937,907,000 | 59,771,000 | 878,136,000 | -249,068,000 |
| Dec 2024 | 8,553,000 | -200,165,000 | -182,819,000 | 483,110,000 | 37,660,000 | 445,450,000 | -131,757,000 |
| Dec 2023 | 2,447,000 | -126,373,000 | -123,277,000 | 87,948,000 | 18,279,000 | 69,669,000 | -111,136,000 |
| Dec 2022 | 0 | -214,986,000 | -214,029,000 | 115,128,000 | 39,022,000 | 76,106,000 | -185,043,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-339,126,000
OpCashFlow TTM
—
Assets (Latest)
$1,390,102,000
Forward EPS
$-9.79
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $260.00 · spot: $305.19 · call volume: 70 · put volume: 581
Expected Move to 2028-01-21:
±$158.84
(52.05%) —
implied range
$146.35 –
$464.03
· ATM straddle on $310.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $8.53B | $10.67 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.91B | $93.81 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.07B | $124.67 | — |
| TGTX | TG THERAPEUTICS, INC. | $9.48B | $62.71 | — |
News headlines (Yahoo Finance, 1h cache)
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
2026-11-12 21:30 · Yahoo
Guggenheim highlights top biotechnology stock
2026-11-12 19:43 · Yahoo
Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value
2026-11-10 00:16 · Yahoo
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-09 12:00 · Yahoo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?
2026-10-28 13:10 · Yahoo
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
2026-10-27 20:01 · Yahoo
Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?
2026-10-18 21:12 · Yahoo
Praxis (PRAX) Q2 2026 Earnings Call Transcript
2026-08-13 16:29 · Yahoo
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?
2026-08-08 22:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.